{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:52:10Z","timestamp":1791085930415,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"DOI":"10.1097\/qai.0b013e31824d006e","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T21:57:38Z","timestamp":1329515858000},"page":"33-42","source":"Crossref","is-referenced-by-count":137,"title":["Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1\u2013Infected Patients"],"prefix":"10.1097","volume":"60","author":[{"given":"Calvin J.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Saag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuanchai","family":"Supparatpinyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herta","family":"Crauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence T.","family":"Rimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R5-6-20210131","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":". Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"R6-6-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":". Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"R7-6-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":". Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.","volume":"59","author":"Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 1","key":"R8-6-20210131","first-page":"A51","article-title":". Screening and baseline mutations in the TMC278 phase III trials ECHO and THRIVE: prevalence and impact on virological response abstract 41.","volume":"16","author":"Vingerhoets","year":"2011","journal-title":"Antivir Ther"},{"key":"R12-6-20210131","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/QAD.0b013e32833032ed","article-title":". Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.","volume":"24","author":"Pozniak","year":"2010","journal-title":"AIDS"},{"key":"R13-6-20210131","first-page":"138","article-title":". Update of the drug resistance mutations in HIV-1: December 2009.","volume":"17","author":"Johnson","year":"2009","journal-title":"Top HIV Med"},{"key":"R14-6-20210131","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/422143","article-title":". Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.","volume":"39","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R15-6-20210131","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":". Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.","volume":"39","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R16-6-20210131","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.qai.0000147521.34369.c9","article-title":". Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.","volume":"38","author":"Moyle","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-6-20210131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":". Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudinelamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changesa 96-week analysis.","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-6-20210131","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":". Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R21-6-20210131","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1310\/hct1206-313","article-title":". Effect of baseline characteristics on the efficacy and safety of once-daily darunavirritonavir in HIV-1-infected, treatment-navie ARTEMIS patients at week 96.","volume":"12","author":"Fourie","year":"2011","journal-title":"HIV Clin Trials"},{"key":"R22-6-20210131","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-146-8-200704170-00007","article-title":". Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.","volume":"146","author":"Nachega","year":"2007","journal-title":"Ann Intern Med"},{"key":"R23-6-20210131","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/10872910151133729","article-title":". Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.","volume":"15","author":"Knobel","year":"2001","journal-title":"AIDS Patient Care STDS"},{"key":"R24-6-20210131","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/aid.2008.0035","article-title":". Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy.","volume":"24","author":"Goldman","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R25-6-20210131","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00007691-200002000-00026","article-title":". Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection.","volume":"22","author":"Back","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R26-6-20210131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/135965350200700103","article-title":". Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.","volume":"7","author":"Mocroft","year":"2002","journal-title":"Antivir Ther"},{"key":"R27-6-20210131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":". Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R28-6-20210131","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":". Efficacy and safety of once-daily darunavirritonavir versus lopinavirritonavir in treatment-naive HIV-1-infected patients at week 48.","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"R29-6-20210131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","article-title":". Once-daily atazanavirritonavir compared with twice-daily lopinavirritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R30-6-20210131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1345\/aph.1M359","article-title":". Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.","volume":"44","author":"Adams","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R32-6-20210131","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":". TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-6-20210131","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/QAI.0b013e31823aca74","article-title":". The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.","volume":"59","author":"Kulkarni","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 1","key":"R35-6-20210131","first-page":"A20","article-title":". Impact of the interactions of rilpivirine (E138K) and lamivudineemtricitabine (M184VI) resistance mutations on viral DNA synthesis and fitness of HIV-1 abstract 12.","volume":"16","author":"Hu","year":"2011","journal-title":"Antivir Ther"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201205010-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:38:51Z","timestamp":1786048731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201205010-00006"}},"subtitle":["Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials"],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31824d006e","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5,1]]}}}